| Pair Name | Hyperoside, Paclitaxel | ||
| Phytochemical Name | Hyperoside (PubChem CID: 5281643 ) | ||
| Anticancer drug Name | Paclitaxel (PubChem CID: 36314 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Hyperoside, Paclitaxel | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Activity | CASP3 | hsa836 | |
| Up-regulation | Expression | IL6 | hsa3569 | |
| Down-regulation | Expression | RELA | hsa5970 | |
| Down-regulation | Activity | TLR4 | hsa7099 | |
| In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
| HCC1806 | Breast squamous cell carcinoma, acantholytic variant | Homo sapiens (Human) | CVCL_1258 | |
| Result | Hyperoside may elevate breast cancer cell sensitivity to paclitaxel by blocking TLR4 activation-mediated pro-inflammatory and pro-survival approaches, thereby endorsing its usefulness as a promising therapeutic combination to overcome chemosensitivity in breast cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling. Mol Cell Probes. 2020 Oct;53:101602. doi: 10.1016/j.mcp.2020.101602. | Click |
